东方生物(688298) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥182,922,481.69, representing a decrease of 51.36% compared to the same period last year[5] - The net profit attributable to shareholders was -¥67,353,495.40, a decline of 33.82% year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥109,011,042.72, reflecting a significant decrease of 281.26%[5] - The net cash flow from operating activities was -¥211,864,976.91, an increase in outflow of 71.04% compared to the previous year[5] - The company's main business revenue for Q1 2024 was RMB 183 million, a significant decline from RMB 372 million in the same period last year, primarily due to higher management and R&D expenses[13] - Net loss for Q1 2024 was ¥69,955,283.74, compared to a net loss of ¥46,412,877.00 in Q1 2023, representing an increase in loss of 50.9%[20] - The company reported a gross profit margin of -47.0% in Q1 2024, compared to -38.9% in Q1 2023[20] Research and Development - Research and development expenses totaled ¥71,964,517.95, an increase of 38.65% year-over-year[5] - The proportion of R&D expenses to operating revenue was 39.34%, up by 25.54 percentage points from the previous year[6] - Research and development expenses for Q1 2024 were ¥71,964,517.95, an increase of 38.7% compared to ¥51,904,828.32 in Q1 2023[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,759,354,189.43, a decrease of 2.63% from the end of the previous year[6] - The company's total assets amounted to ¥8,759,354,189.43, a decrease from ¥8,995,951,150.74 in the previous year[18] - Total liabilities decreased to ¥1,222,534,023.61 from ¥1,446,223,002.71, reflecting a reduction of 15.5%[18] - As of March 31, 2024, the total current assets amounted to RMB 5.27 billion, down from RMB 5.90 billion at the end of 2023[16] - The total long-term investments decreased slightly to RMB 20.37 million from RMB 21.24 million[16] Shareholder Information - The company had a total of 16,045 common shareholders at the end of the reporting period[10] - The top three shareholders collectively hold 48.56% of the company, with Anji Fulanglai Import and Export Trade Co., Ltd. owning 19.50%[12] Cash Flow and Financing Activities - In Q1 2024, the company reported cash inflows from operating activities of CNY 228,718,943.11, a slight decrease from CNY 235,205,118.36 in Q1 2023[23] - The net cash outflow from operating activities was CNY -211,864,976.91, improving from CNY -731,563,866.64 in the same period last year[23] - Investment activities generated a net cash outflow of CNY -100,731,912.72, compared to CNY -56,819,148.88 in Q1 2023[23] - The company received CNY 532,446,296.68 from investment recoveries, significantly higher than CNY 211,000,000.00 in the previous year[23] - Cash and cash equivalents at the end of Q1 2024 totaled CNY 2,595,292,577.44, down from CNY 6,229,181,276.83 at the end of Q1 2023[24] - The company reported cash inflows from financing activities of CNY 105,960,000.00, a decrease from CNY 500,000,000.00 in Q1 2023[24] - The net cash outflow from financing activities was CNY -30,026,504.17, compared to a net inflow of CNY 498,216,180.60 in the same quarter last year[24] Other Information - The company has not disclosed any significant new product developments or market expansion strategies in the current report[13] - The company has not participated in any financing or margin trading activities during the reporting period[12] - The company experienced a foreign exchange impact of CNY 9,312,629.07 on cash and cash equivalents[24] - The company paid CNY 20,847,373.53 in taxes during Q1 2024, down from CNY 103,378,871.24 in the previous year[23]